Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company focused on psychiatry and other central nervous system disorders. Founded in 2019 and based in Mountain View, California, it is building a Precision Psychiatry Platform that uses neurobiology and data science to identify biomarkers and match patients to treatments more likely to work for them. The company’s pipeline includes seven clinical-stage assets across major depressive disorder, bipolar depression, treatment-resistant depression, schizophrenia, and Parkinson’s disease. Alto is still in development mode, with no commercial products and no internal manufacturing footprint, and relies on third-party partners for clinical supply and future commercialization support.
15.69
15.69
| % | |
|---|---|
| Precision psychiatry platform | 0% Proprietary neurobiology and data-science tools used to identify biomarkers and stratify patients for clinical development. |
| Clinical-stage CNS drug candidates | 100% Investigational therapies targeting depression, schizophrenia, and Parkinson’s disease across multiple mechanisms. |
Alto does not currently sell commercial products, so its near-term customers are primarily clinical trial participants,...
Patients enrolled in Alto’s studies for MDD, schizophrenia, TRD, bipolar depression, and Parkinson’s disease to generate efficacy and biomarker data.
Hospitals, clinics, and trial sites that administer protocols and collect data needed to advance the pipeline.
Future prescribers who would use Alto’s approved products if development succeeds, especially in hard-to-treat CNS disorders.
Potential licensing or commercialization partners, especially outside the United States, that could help launch approved products.
Alto is headquartered in Mountain View, California and is incorporated in Delaware, with operations centered in the...
Alto’s strategy is to build a differentiated psychiatry pipeline around biomarker-based patient stratification rather...
The company has no commercial revenue, so value creation depends on generating positive clinical data and moving assets toward regulatory milestones.
As a clinical-stage company with limited resources, Alto needs to concentrate spending on programs with the best probability of value creation.
Biomarker-based patient selection is intended to improve clinical success rates and create a competitive moat versus untargeted CNS drug development.
If products are approved, Alto will need a scalable launch model and may need partners outside the U.S. to reach global markets efficiently.
Alto faces the core risks of a clinical-stage biopharmaceutical company: no approved products, no commercial revenue,...
The company’s value depends on positive data from seven clinical-stage assets, and any trial setback could materially reduce pipeline value.
Alto expects to need substantial additional capital to fund operations and clinical development beyond its current runway.
The company relies on CROs and CMOs for clinical execution and supply, so delays or quality issues can slow development.
Larger biopharma and biotech competitors may reach approval faster or commercialize more effectively in psychiatry and neuroscience.
Clinical and biomarker data are sensitive, and breaches or system disruptions could impair trials and damage trust.
AIFF · Services-Prepackaged Software
ALTO · Industrial Organic Chemicals
SILO · Pharmaceutical Preparations
PMN · Pharmaceutical Preparations
JUNS · Pharmaceutical Preparations
MPLT · Pharmaceutical Preparations
: 11/08/2026